Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZF2001 Sequential Booster Immunogenicity and Safety Study
NCT05089045Completed
- Sponsor
- Zhifei Biological
- Start
- Aug 2021
- Primary completion
- Sep 2021
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Open-label, single-arm trial of ZF2001 in coronavirus disease 2019 (COVID-19), sponsored by Zhifei Biological. Primary endpoints: Number of adverse events after intramuscular injection at 1 month and Immunogenic end point at 14 days. Started Aug 2021; status: completed.
02
Drugs
ZF2001
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05089045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05089045.